72 related articles for article (PubMed ID: 12882706)
1. [The short-term outcomes of patients with acute leukemia treated by thalidomide].
Wang ML; Mu HR; Liu YF; Li YG; Wu HG; Sui HT
Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):296-9. PubMed ID: 12882706
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
3. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
4. [Study on the role of angiogenesis and related factors in leukemias].
Zhang Y; Gu J; Wang M; Ma L; Wang XL; He B; Sun M
Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):175-8. PubMed ID: 15946533
[TBL] [Abstract][Full Text] [Related]
5. [The clinical significance of angiogenesis in the bone marrow of acute leukemia patients].
Ye XJ; Wang LJ; Lin MF; Ding W
Zhonghua Nei Ke Za Zhi; 2003 Jul; 42(7):486-9. PubMed ID: 12921610
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
8. [Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia].
Wang C; Chen FY; Zhu JS; Xu YP; Han JY; Ouyang RR
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):845-8. PubMed ID: 15634546
[TBL] [Abstract][Full Text] [Related]
9. [Change of vascular endothelial growth factor and its receptors expression in acute myeloid leukemia before and after treatment].
Zhang JQ; Wang JK; Li YM
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):100-2. PubMed ID: 14990052
[TBL] [Abstract][Full Text] [Related]
10. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of serum VEGF and bFGF in children with acute leukemia].
Hong-bing H; Wen-yi X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1019-20. PubMed ID: 22125837
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
14. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Barr P; Fu P; Lazarus H; Kane D; Meyerson H; Hartman P; Reyes R; Creger R; Stear K; Laughlin M; Tse W; Cooper B
Leuk Lymphoma; 2007 Oct; 48(10):1940-9. PubMed ID: 17917962
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Ge ZZ; Chen HM; Gao YJ; Liu WZ; Xu CH; Tan HH; Chen HY; Wei W; Fang JY; Xiao SD
Gastroenterology; 2011 Nov; 141(5):1629-37.e1-4. PubMed ID: 21784047
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
18. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
19. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H
Br J Haematol; 2003 Nov; 123(3):436-41. PubMed ID: 14617002
[TBL] [Abstract][Full Text] [Related]
20. [Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Zhai Y; Lu ZJ
Ai Zheng; 2003 Dec; 22(12):1301-6. PubMed ID: 14693056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
